Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, is strengthening its foothold in the U.S. by launching a new office in Cambridge, Massachusetts. This expansion positions the company strategically within the Boston area, facilitating closer collaboration with biotechnology and pharmaceutical firms. By establishing a presence in this key life-sciences hub, IAG aims to enhance its partnerships and offer more localized support for clinical trials in the region.
The Cambridge office will bolster IAG’s efforts across various therapeutic domains such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic conditions. It will also promote more efficient cooperation with sponsors and contract research organizations engaged in Phase I-III clinical trials and programs with intensive imaging requirements. The company plans to generate local employment opportunities, focusing on hiring for roles in clinical imaging operations, data science, regulatory support, and business development over the next one to two years.
Key to IAG’s expansion is the provision of comprehensive imaging services, which include clinical trial design consultation, imaging protocol optimization, centralized image analysis, and the delivery of regulatory-compliant data. By embedding itself within the Boston life-sciences ecosystem, IAG aims to foster improved collaboration with biotechnology companies, pharmaceutical firms, academic institutions, and clinical research centers.
Globally, IAG supports clinical trials spanning North America, Europe, and the Asia-Pacific region. The company partners with pharmaceutical, biotechnology, and medical technology companies and contract research organizations (CROs) to manage multi-center studies. Its international operations ensure standardized imaging protocols, centralized data harmonization, and consistent imaging analysis across all trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO). It aids pharmaceutical, biotechnology, and medical technology firms by focusing on imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight, supporting a range of indications including oncology, inflammatory disease, musculoskeletal, cardiometabolic, and rare diseases.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.
